Effectiveness and safety of mogamulizumab for the treatment of Sézary syndrome in very elderly patients: A real‐world, multicentre, retrospective study conducted in France.

A retrospective study conducted in France examined the effectiveness and safety of mogamulizumab in very elderly patients with Sézary syndrome (SS), a rare form of cutaneous T-cell lymphoma. Nine patients aged 85 years and older received mogamulizumab, with 67% achieving an objective response lasting at least 4 months. The study found that mogamulizumab was well-tolerated in this age group, with some patients experiencing treatment-emergent adverse events. The results suggest that mogamulizumab may be a viable treatment option for very elderly patients with SS, comparable to its effectiveness in younger patients. [Extracted from the article]